These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study]. Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. Chen FP; Chang CJ; Chao AS; Huang HY; Huang JP; Wu MH; Tsai CC; Kung FT; Chang CW; Tsai YC Taiwan J Obstet Gynecol; 2016 Jun; 55(3):336-40. PubMed ID: 27343311 [TBL] [Abstract][Full Text] [Related]
25. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280 [TBL] [Abstract][Full Text] [Related]
26. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518 [TBL] [Abstract][Full Text] [Related]
27. Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy. Hammar M; Ekblad S; Lönnberg B; Berg G; Lindgren R; Wyon Y Maturitas; 1999 Jan; 31(2):117-22. PubMed ID: 10227004 [TBL] [Abstract][Full Text] [Related]
28. Resistance training for hot flushes in postmenopausal women: A randomised controlled trial. Berin E; Hammar M; Lindblom H; Lindh-Åstrand L; Rubér M; Spetz Holm AC Maturitas; 2019 Aug; 126():55-60. PubMed ID: 31239119 [TBL] [Abstract][Full Text] [Related]
29. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Simon JA; Menopause; 2006; 13(2):222-31. PubMed ID: 16645536 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P; Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083 [TBL] [Abstract][Full Text] [Related]
31. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Baerug U; Winge T; Nordland G; Faber-Swensson E; Heldaas K; Norling B; Larsen S; Arce JC Climacteric; 1998 Sep; 1(3):219-28. PubMed ID: 11907946 [TBL] [Abstract][Full Text] [Related]
32. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. D'Anna R; Cannata ML; Atteritano M; Cancellieri F; Corrado F; Baviera G; Triolo O; Antico F; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Marini H; Squadrito F Menopause; 2007; 14(4):648-55. PubMed ID: 17251874 [TBL] [Abstract][Full Text] [Related]
33. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973 [TBL] [Abstract][Full Text] [Related]
34. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Archer DF; Menopause; 2003; 10(6):516-21. PubMed ID: 14627859 [TBL] [Abstract][Full Text] [Related]
35. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ Gynecol Endocrinol; 2001 Oct; 15(5):349-58. PubMed ID: 11727357 [TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307 [TBL] [Abstract][Full Text] [Related]
37. Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes. Cunha EP; Azevedo LH; Pompei LM; Strufaldi R; Steiner ML; Ferreira JA; Peixoto S; Fernandes CE Climacteric; 2010 Aug; 13(4):362-7. PubMed ID: 20151792 [TBL] [Abstract][Full Text] [Related]
38. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Notelovitz M; Mattox JH Menopause; 2000; 7(5):310-7. PubMed ID: 10993030 [TBL] [Abstract][Full Text] [Related]
39. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. D'Anna R; Cannata ML; Marini H; Atteritano M; Cancellieri F; Corrado F; Triolo O; Rizzo P; Russo S; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Adamo EB; Squadrito F Menopause; 2009; 16(2):301-6. PubMed ID: 19034051 [TBL] [Abstract][Full Text] [Related]
40. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Rovati LC; Setnikar I; Genazzani AR Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]